IC
ICU.US SeaStar Medical Holding Corporation
- Market cap
- USD 4.46M
- P/E
- -
- P/B
- 1.04x
- ROE
- -3,349.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ICU.US undervalued?
Graham numberThe Graham number of SeaStar Medical Holding Corporation cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
SeaStar Medical Holding Corporation fundamental analysis
No fundamental analysis for SeaStar Medical Holding Corporation yet.
SeaStar Medical Holding Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About SeaStar Medical Holding Corporation
SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute ki…
Full company profileSeaStar Medical Holding Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
SeaStar Medical Holding Corporation annual financial statements
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 135K | 1.23M | 2.33M |
| Gross Profit | - | - | - | 0.00 | 135K | 1.18M | 2.13M |
| Operating Income | -6.45M | -4.45M | -11.6M | -14.2M | -17.8M | -12.2M | -16.0M |
| EBITDA | -5.24K | -4.39M | -11.6M | -11.1M | -24.6M | -12.1M | -15.7M |
| Net Income | -3.28M | -4.60M | -23.0M | -26.2M | -24.8M | -12.2M | -15.7M |
| EPS | -63 | -88 | -441 | -303 | -66 | -0.59 | -3.58 |
| Balance Sheet | |||||||
| Total Assets | 2.91M | 603K | 3.04M | 3.51M | 4.66M | 14.2M | 5.31M |
| Total Liabilities | 74.5M | 3.42M | 23.8M | 17.4M | 6.84M | 3.74M | 4.84M |
| Shareholders' Equity | -71.6M | -2.82M | -20.8M | -13.9M | -2.18M | 10.4M | 469K |
| Cash & Short-term Investments | 2.81M | 510K | 47.0K | 176K | 1.82M | 12.0M | 3.99M |
| Total Debt | 83.0K | 2.62M | 8.83M | 9.08M | 574K | 525K | - |
| Cash Flow | |||||||
| Operating Cash Flow | -5.57M | -5.11M | -7.79M | -10.3M | -16.0M | -13.6M | -12.2M |
| Capital Expenditure | 5.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -5.57M | -5.11M | -7.79M | -10.3M | -16.0M | -13.6M | -12.2M |
| Ratios | |||||||
| ROE | - | - | - | - | - | -116.6% | -3,349.0% |
| ROA | -112.6% | -762.2% | -757.5% | -746.7% | -533.1% | -85.8% | -295.8% |
| Net Profit Margin | - | - | - | - | -18,392.6% | -984.6% | -675.1% |
| Debt to Equity | - | - | - | - | - | 0.05x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
SeaStar Medical Holding Corporation dividends
SeaStar Medical Holding Corporation has not paid dividends in the last 6 fiscal years.
Last stock split: 1:10 on Jan 5, 2026.
Who owns SeaStar Medical Holding Corporation
- Insiders 1.57%
- Institutions 8.79%
- Public & others 89.65%
- Shares outstanding 5.32M
- Free float 4.37M
Top funds holding ICU.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 20.5K | 0.39% | -0.38% | Sep 2026 |
| Abante Quant Value FI | 11.4K | 0.21% | 0.00% | Aug 2026 |
| Fidelity Total Market Index | 8.66K | 0.16% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 7.16K | 0.13% | 0.00% | Aug 2026 |
| Fidelity Series Total Market Index | 5.81K | 0.11% | 0.00% | Sep 2026 |
| DFA U.S. Vector Equity I | 3.74K | 0.07% | 0.00% | Sep 2026 |
| Dimensional US Core Equity 2 ETF | 2.84K | 0.05% | 0.00% | Oct 2026 |
| DFA US Vector Equity Class F | 2.80K | 0.05% | 0.00% | Aug 2026 |
| Vanguard U.S. Eq Idx £ Acc | 165.00 | 0.00% | 0.00% | Sep 2026 |
Top institutions holding ICU.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Geode Capital Management, LLC | 49.6K | 0.94% | -10.87% | Jun 2026 |
| Vanguard Capital Management, LLC | 33.1K | 0.63% | +14.94% | Jun 2026 |
| UBS Group AG | 31.4K | 0.60% | +3,859.39% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 13.7K | 0.26% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 12.6K | 0.24% | -54.81% | Jun 2026 |
| Northern Trust Corp | 10.4K | 0.20% | 0.00% | Jun 2026 |
| PNC Financial Services Group Inc | 4.94K | 0.09% | +182.78% | Jun 2026 |
| Tower Research Capital LLC | 1.36K | 0.03% | -2.80% | Jun 2026 |
| BlackRock Inc | 913.00 | 0.02% | 0.00% | Jun 2026 |
| Advisor Group Holdings, Inc. | 195.00 | 0.00% | -15.22% | Jun 2026 |
| Goss Wealth Management LLC | 176.00 | 0.00% | 0.00% | Jun 2026 |
| Vanguard Global Advisers, LLC | 165.00 | 0.00% | 0.00% | Jun 2026 |
| TD Waterhouse Canada Inc | 22.00 | 0.00% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 14.00 | 0.00% | 0.00% | Jun 2026 |
| SOA Wealth Advisors, LLC. | 6.00 | 0.00% | 0.00% | Jun 2026 |
| Barclays PLC | 4.00 | 0.00% | 0.00% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 2.00 | 0.00% | 0.00% | Jun 2026 |
| Mercer Global Advisors Inc. | 1.00 | 0.00% | 0.00% | Jun 2026 |
| GREAT VALLEY ADVISOR GROUP, INC. | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 0.00 | 0.00% | -100.00% | Jun 2026 |
SeaStar Medical Holding Corporation company profile
- Company name
- SeaStar Medical Holding Corporation
- Ticker
- ICU.US
- Exchange
- USA Stocks
- Listed since
- Oct 28, 2022
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 18
- Fiscal year end
- December
- Address
- 3513 Brighton Boulevard, Denver, CO, United States, 80216
- Phone
- 844 427 8100
- Website
- seastarmedical.com
About SeaStar Medical Holding Corporation
SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis. It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease. SeaStar Medical Holding Corporation was founded in 2007 and is headquartered in Denver, Colorado.
SeaStar Medical Holding Corporation management
8- Mr. Eric SchlorffCEO, Treasurer, President & Executive Director · born 1973
- Mr. Michael Messinger CPAChief Financial Officer · born 1975
- Colonel Kevin Chung FACP, M.D.Chief Medical Officer · born 1973
- Dr. H. David Humes M.D.Co-Founder & Scientific Advisor
- Mr. Tom MullenVice President of Operations & Product Development
- Mr. Bradford K. Towne CPAController & Principal Accounting Officer · born 1978
- Mr. Tim VaracekSenior Vice President of Commercial & Business Operations
- Mr. Sai P. Iyer Ph.D.Senior Vice President of Medical Affairs & Research